双氯芬酸二乙胺
双氯芬酸二乙胺 性质
| 熔点 | 145-148°C |
|---|---|
| 储存条件 | Inert atmosphere,Room Temperature |
| 溶解度 | DMF：30mg/mL； DMSO：10mg/mL；乙醇：30mg/mL； PBS（pH 7.2）：2 mg/mL |
| 形态 | 结晶固体 |
| 稳定性 | 吸湿性 |
| CAS 数据库 | 78213-16-8(CAS DataBase Reference) |
双氯芬酸二乙胺 用途与合成方法
|
Human COX-2 1.3 nM (IC 50 , in CHO cells) |
Human COX-1 4 nM (IC 50 , in CHO cells) |
Ovine COX-2 0.84 μM (IC 50 ) |
Ovine COX-1 5.1 μM (IC 50 ) |
Diclofenac diethylamine抗炎，退热，和镇痛作用的主要作用机制被认为是通过抑制环氧合酶(COX)，从而抑制前列腺素合成。它通过抑制细菌DNA合成发挥出抑菌活性。COX的抑制也会减少胃上皮细胞中的前列腺素，使其对胃酸的腐蚀更敏感。这也是diclofenac diethylamine的主要副作用。Diclofenac diethylamine阻断COX2-同工酶(大约10倍)，具有低到中度的选择性，因此，diclofenac diethylamine造成的胃肠疾病的发生率比消炎痛和阿司匹林低。
Diclofenac (3 mg/kg, b.i.d., for 5 days) significantly increases faecal
51
Cr excretion in rats, and such effect is also observed in squirrel monkeys after administrated of 1 mg/kg twice daily for 4 days.
Diclofenac (10 mg/kg; administered via oral route just prior to induction of inflammation) shows in vivo anti-inflammatory activity in Wistar rats.
| Animal Model: | Male Sprague-Dawley rats (150±200 g) |
| Dosage: | 3 mg/kg |
| Administration: | Oral administration, b.i.d., for 5 days |
| Result: | Resulted in a significant increase in faecal 51 Cr excretion. |
| Animal Model: | Wistar rats (150-175 g) bearing Formalin-induced rat foot paw edema model |
| Dosage: | 10 mg/kg |
| Administration: | Administered via oral route just prior to induction of inflammation |
| Result: | Showed in vivo anti-inflammatory activity (% edema inhibition=29.2, 1 h; 22.2, 3 h; 20, 6 h). |
双氯芬酸二乙胺 化学药品说明书
双氯芬酸二乙胺 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-01-25 | HY-15036A | 双氯芬酸二乙胺 | 78213-16-8 | 500mg | 350 |
| 2024-01-25 | HY-15036A | 双氯芬酸二乙胺 | 78213-16-8 | 5G | 484 |
